abstract |
The present invention provides a combination therapy comprising an anti-hyaluronan preparation, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-target taxane, and optionally an additional chemotherapeutic agent such as a nucleoside analog . Combination therapy can be used in methods of treating cancer and especially solid tumor cancers. |